Discovery and structure-activity relationships of small molecules that block the human immunoglobulin G-human neonatal Fc receptor (hIgG-hFcRn) protein-protein interaction.

The neonatal Fc receptor, FcRn, prolongs the half-life of IgG in the serum and represents a potential therapeutic target for the treatment of autoimmune disease. Small molecules that block the protein-protein interactions of human IgG-human FcRn may lower pathogenic autoantibodies and provide effective treatment. A novel class of quinoxalines has been discovered as antagonists of the IgG:FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.
AuthorsZhaolin Wang, Cara Fraley, Adam R Mezo
JournalBioorganic & medicinal chemistry letters (Bioorg Med Chem Lett) Vol. 23 Issue 5 Pg. 1253-6 (Mar 1 2013) ISSN: 1464-3405 [Electronic] England
PMID23375228 (Publication Type: Journal Article)
CopyrightCopyright © 2013 Elsevier Ltd. All rights reserved.
Chemical References
  • Fc receptor, neonatal
  • Histocompatibility Antigens Class I
  • Immunoglobulin G
  • Ligands
  • Quinoxalines
  • Receptors, Fc
  • Drug Evaluation, Preclinical
  • Histocompatibility Antigens Class I (immunology, metabolism)
  • Humans
  • Immunoglobulin G (immunology, metabolism)
  • Ligands
  • Protein Interaction Domains and Motifs (drug effects)
  • Quinoxalines (pharmacology)
  • Receptors, Fc (antagonists & inhibitors, immunology, metabolism)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: